{"title":"基于白蛋白的抗癌药物载体研究进展","authors":"Ruoli Zhou, Rongbin Zhong, Zhonghui Luo, Hua Wei, Cui-Yun Yu","doi":"10.1002/anbr.202500011","DOIUrl":null,"url":null,"abstract":"<p>Albumin is the most abundant protein in plasma, featuring a unique chemical structure and conformation that underpins its functions. Its excellent biocompatibility, nontoxicity and non-immunogenicity make it an ideal carrier for encapsulating therapeutic agents, particularly in controlled release applications for cancer treatment. Although existing reviews focus on albumin-based particulate delivery systems, there is a lack of comprehensive analysis from the perspective of using albumin's structural characteristics and binding sites for drug delivery. This review categorizes albumin's drug-loading modes based on its surface-active groups and internal binding sites, emphasizing drug-loading strategies and targeting mechanisms. It also details the preparation and modification methods for albumin nanoparticles, along with clinical performance evaluations. Finally, it addresses current challenges and proposes potential solutions. This review aims to provide valuable insights for developing advanced albumin-based anticancer drugs with enhanced therapeutic efficacy.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 9","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500011","citationCount":"0","resultStr":"{\"title\":\"Advances on Albumin-Based Carriers for Anticancer Drug Delivery\",\"authors\":\"Ruoli Zhou, Rongbin Zhong, Zhonghui Luo, Hua Wei, Cui-Yun Yu\",\"doi\":\"10.1002/anbr.202500011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Albumin is the most abundant protein in plasma, featuring a unique chemical structure and conformation that underpins its functions. Its excellent biocompatibility, nontoxicity and non-immunogenicity make it an ideal carrier for encapsulating therapeutic agents, particularly in controlled release applications for cancer treatment. Although existing reviews focus on albumin-based particulate delivery systems, there is a lack of comprehensive analysis from the perspective of using albumin's structural characteristics and binding sites for drug delivery. This review categorizes albumin's drug-loading modes based on its surface-active groups and internal binding sites, emphasizing drug-loading strategies and targeting mechanisms. It also details the preparation and modification methods for albumin nanoparticles, along with clinical performance evaluations. Finally, it addresses current challenges and proposes potential solutions. This review aims to provide valuable insights for developing advanced albumin-based anticancer drugs with enhanced therapeutic efficacy.</p>\",\"PeriodicalId\":29975,\"journal\":{\"name\":\"Advanced Nanobiomed Research\",\"volume\":\"5 9\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500011\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Nanobiomed Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://advanced.onlinelibrary.wiley.com/doi/10.1002/anbr.202500011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/anbr.202500011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Advances on Albumin-Based Carriers for Anticancer Drug Delivery
Albumin is the most abundant protein in plasma, featuring a unique chemical structure and conformation that underpins its functions. Its excellent biocompatibility, nontoxicity and non-immunogenicity make it an ideal carrier for encapsulating therapeutic agents, particularly in controlled release applications for cancer treatment. Although existing reviews focus on albumin-based particulate delivery systems, there is a lack of comprehensive analysis from the perspective of using albumin's structural characteristics and binding sites for drug delivery. This review categorizes albumin's drug-loading modes based on its surface-active groups and internal binding sites, emphasizing drug-loading strategies and targeting mechanisms. It also details the preparation and modification methods for albumin nanoparticles, along with clinical performance evaluations. Finally, it addresses current challenges and proposes potential solutions. This review aims to provide valuable insights for developing advanced albumin-based anticancer drugs with enhanced therapeutic efficacy.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
